Playback speed
10 seconds
EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax for Treatment-Naïve CLL/SLL With Del(17p) and/or TP53
By
Insights from 2024 EHA Annual Meeting
FEATURING
Paolo Ghia
By
Insights from 2024 EHA Annual Meeting
FEATURING
Paolo Ghia
0 views
June 28, 2024
Comments 0
Login to view comments.
Click here to Login